Stocks
CymaBay Therapeutics, Inc.CBAY
NASDAQHealthcareBiotechnology$32.48+0.03%
A clinical-stage biopharmaceutical company focused on developing therapies for chronic liver and metabolic diseases. Its lead drug candidate, seladelpar, targets primary biliary cholangitis (PBC) and has been the central driver of investor attention due to late-stage clinical results and regulatory ...
Market Cap: $3.7B52W Range: $7.26 – $32.50
This page tracks all publicly disclosed congressional trades in CymaBay Therapeutics, Inc. (CBAY), a company in the Healthcare sector. All data is sourced from STOCK Act Periodic Transaction Reports filed with the House and Senate disclosure offices.
Total Disclosures
0
Unique Politicians
0
Buys
0
Sells
0
Congressional Trading History
No congressional trades found for this stock.